Table 1.
Meta-analyses included for induction of clinical remission in Crohn’s disease
| Study | Intervention | Comparator | Follow-up | n | Induction of clinical remission, RR (95%CI) | Quality of evidence |
| Chande et al[23] | AZA or 6-MP | Placebo | 6 wk-9 mo | 380 | RR 1.23 (0.97-1.55)1 | Moderate |
| AZA or 6-MP | MTX | 6 wk-9 mo | 143 | RR 1.13 (0.85-1.49)1 | Low | |
| AZA or 6-MP | 5-ASA | 6 wk-9 mo | 156 | RR 1.24 (0.80-1.91)1 | Very low | |
| AZA | IFX | 26 wk | 399 | RR 0.66 (0.51-0.87)1 | Moderate |
1
Clinical remission as measured by individual study with a validated outcome (e.g., Crohn’s Disease Activity Index score < 150 points or a Harvey-Bradshaw Index score < 3). 5-ASA: 5-aminosalicylic acid; 6-MP: 6-mercaptopurine; AZA: Azathioprine; CI: Confidence interval; IFX: Infliximab; MTX: Methotrexate; n: Number of patients; RR: Risk ratio.